SLC7A11 and central nervous system cancer: Additionally, the expression of xCT/SLC7A11 in patient glioma tissue correlates with the peritumoral glutamate response to sulfasalazine, suggesting its potential as a predictive biomarker for the efficacy of sulfasalazine in modulating glutamate release [65].